BiologIC-technologieën helpen bij het implementeren van warmte-inactivering met hoge doorvoer van patiëntmonsters in Cambridge Lighthouse Laboratory
CAMBRIDGE, Engeland – (BUSINESS WIRE) – BiologIC Technologies, een pionier in Industrie 4.0-technologieën voor de biorevolutie, heeft samengewerkt met AstraZeneca en Electrolux Professional om een high-throughput-oplossing te implementeren voor warmte-inactivering van patiëntmonsters in het Cambridge Lighthouse Laboratory. Deze oplossing maakt het virus niet-infectieus, wat de veiligheid, duurzaamheid en schaalbaarheid van het testproces vergroot.
Het Cambridge Lighthouse Laboratory, opgericht door AstraZeneca, de Universiteit van Cambridge en GlaxoSmithKline, en vervolgens in samenwerking met Charles River Laboratories, maakte deel uit van het netwerk van Lighthouse-laboratoria van NHS Test and Trace, dat diagnostische tests voor de hele bevolking uitvoert.
BiologIC, AstraZeneca en Electrolux Professional combineerden biowetenschap en thermische expertise om snel een innovatieve, productieklare oplossing voor warmte-inactivering te implementeren in dit veiligheidskritieke proces. Nauwkeurige validatie toonde de inactivering van het COVID-19-virus aan terwijl de nauwkeurigheid van diagnostische tests gehandhaafd bleef. De partijen hebben deze oplossing nu met succes geïmplementeerd met Skyline Ovens van Electrolux Professional.
BiologIC Technologies Helps Implement High-throughput Heat Inactivation of Patient Samples at Cambridge Lighthouse Laboratory
CAMBRIDGE, England–(BUSINESS WIRE)– BiologIC Technologies, a pioneer in Industry 4.0 technologies for the bio-revolution, has collaborated with AstraZeneca and Electrolux Professional to implement a high-throughput solution for heat inactivation of patient samples at the Cambridge Lighthouse Laboratory. This solution renders the virus non-infectious, enhancing the safety, sustainability and scalability of the testing process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005091/en/
BiologIC Technologies helps implement high-throughput heat inactivation of patient samples at Cambridge UK COVID-19 Test Centre. (Photo: Business Wire)
The Cambridge Lighthouse Laboratory, established by AstraZeneca, the University of Cambridge and GlaxoSmithKline, and subsequently partnering with Charles River Laboratories, was part of NHS Test and Trace’s network of Lighthouse laboratories which provides population-wide diagnostic testing.
BiologIC, AstraZeneca and Electrolux Professional combined bioscience and thermal expertise to rapidly implement an innovative, production-ready heat inactivation solution in this safety-critical process. Rigorous validation demonstrated inactivation of the COVID-19 virus whilst maintaining the accuracy of diagnostic testing. The parties have now successfully implemented this solution, using Skyline Ovens from Electrolux Professional.
Richard Vellacott, CEO of BiologIC Technologies:
“Combined with vaccines, diagnostic testing will be critical to re-mobilising our local, national and international communities, particularly as new strains of COVID-19 continue to evolve. We were pleased to identify, validate and support implementation of this solution to greatly enhance the safety, cost-effectiveness and scalability of COVID-19 diagnostic testing.”
Steve Rees, VP Discovery Biology, R&D, AstraZeneca:
“Our collaborative innovative solution enables virus inactivation upon receipt at the laboratory allowing work on the open bench, which simplifies the workflow, reduces the risk of employee exposure to live virus, and facilitates future innovations around automation of the sample unpackaging process.”
Alberto Zanata, CEO of Electrolux Professional:
“With the advanced technology of the SkyLine combi oven, we support yet another milestone in fighting the pandemic that is affecting people and businesses around the world. We are very proud to play a role in safeguarding the process of handling the COVID-19 samples, to protect all people involved in testing.”
Ends
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005091/en/
Contacts
For further information from BiologIC Technologies
Richard Vellacott, CEO
richard.vellacott@biologic-tech.com
Dr Colin Barker, CSO
colin.barker@biologic-tech.com
Phone: +44(0)1353 725 816